Management of dyslipidemia in Cushing's syndrome

Neuroendocrinology

Volumn 92, Issue SUPPL. 1, 2010, Pages 91-95

  Greenman, Yona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Hyperlipidemia; Ketoconazole

Indexed keywords

ACID LIPASE; ATORVASTATIN; CHOLESTEROL; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOTANE; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADRENALECTOMY; CLINICAL FEATURE; CONFERENCE PAPER; CUSHING SYNDROME; DRUG INDICATION; DYSLIPIDEMIA; HUMAN; HYPERCORTISOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

CUSHING SYNDROME; DYSLIPIDEMIAS; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; MITOTANE;

EID: 77956506949     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314294     Document Type: Conference Paper

References (25)

1. Plotz CM, Knowlton AI, Ragan C: The natural history of Cushing's syndrome. Am J Med 1952; 13: 597-614.
2. Etxabe J, Vasquez JA: Morbidity and mortality in Cushing's disease: and epidemiological approach. Clin Endocrinol 1994; 40:479-484.
3. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Find ling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Ne wel l-Pr ice J, Ni em a n L K, S on i no N, Va nc e ML, Giustina A, Boscaro M: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88:5593-5602. (Pubitemid 38033020)
4. Wei L, MacDonald TM, Walker BR: Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141:764-770.
5. Tauchmanovà L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S, Lombardi G: Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocri-nol Metab 2002; 87:4872-4878.
6. Dekker MJ, Koper JW, Van Aken MO, Pols HA, Hofman A, De Jong FH, Kirschbaum C, Witteman JC, Lamberts SW, Tiemeier H: Salivary cortisol is related to atherosclerosis of carotid arteries. J Clin Endocrinol Metab 2008; 93: 3741-3747.
7. Samra JS, Clark ML, Humphreys SM, Mac-Donald IA, Bannister PA, Frayn KN: Effects of physiological hypercortisolemia on the regulation of lipolysis in subcutaneous adipose tissue. J Clin Endocrinol Metab 1998; 83: 626-631.
8. Van Raalte DH, Ouwens DM, Diamant M: Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93.
9. Kola B, Christ-Crain M, Lolli F, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB, Korbonits M: Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab 2008; 93: 4969-4973.
10. Taskinen MR, Nikkilä EA, Pelkonen R, Sane T: Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. J Clin Endocrinol Metab 1983; 57: 619-626.
11. Fardet L, Cabane J, Kettaneh A, Lebbé C, Flahault A: Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology 2007; 46: 1102-1106.
12. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G: Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84:2664-2672.
13. Faggiano A, Pivonello R, Spiezia S, De Mar-tino MC, Filippella M, Di Somma C, Lom-bardi G, Colao A: Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88: 2527-2533.
14. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G: High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol 2004; 61:768-777.
15. Terzolo M, Allasino B, Bosio S, Brusa E, Daf-fara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A, Camaschella C: Hy-perhomocysteinemia in patients with Cush-ing's syndrome. J Clin Endocrinol Metab 2004; 89: 3745-3751.
16. Erbil Y, Ademolu E, Ozbey N, Barbaros U, Yanik BT, Salmasliölu A, Bozbora A, Ozarmóan S: Evaluation of the cardiovascular risk in patients with subclinical Cush-ing syndrome before and after surgery. World J Surg 2006; 30:1665-1671.
17. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E: Surgical versus conservative management for sub-clinical Cushing syndrome in adrenal inci-dentalomas: a prospective randomized study. Ann Surg 2009; 249:388-391.
18. Danilowicz K, Bruno OD, Manavela M, Gomez RM, Barkan A: Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitar y 2008; 11: 279-285.
19. Igaz P, Tömböl Z, Szabó PM, Likó I, Rácz K: Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. Curr Med Chem 2008; 15:2734-2747.
20. Gylling H, Vanhanen H, Miettinen TA: Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hy percholesterolemia. J Lipid Res 1993; 34: 59-67.
21. Gylling H, Vanhanen H, Miettinen TA: Hy-polipidemic effect and mechanism of keto-conazole without and with cholestyramine in familial hypercholesterolemia. Metabolism 1991; 40: 35-41.
22. Terzolo M, Pia A, Berruti A, Osella G, Alì A, Carbone V, Testa E, Dogliotti L, Angeli A: Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effect sinpatients with adrenocortical cancer. J Clin Endocrinol Metab 2000; 85: 2234-2238.
23. Kawai S, Ichikawa Y, Kaburaki J, Yoshida T: 18 years mitotane therapy for intractable Cushing's disease. Lancet 1999; 354: 951.
24. Maher VM, Trainer PJ, Scoppola A, Anderson J V, Thompson GR, Besser GM: Possible mechanism and treatment of o,p'DDD-in-duced hypercholesterolaemia. Q J Med 1992; 84:671-679.
25. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80:565-581.